Analysis of epithelial-mesenchymal transition markers in the histogenesis of hepatic progenitor cell in HBV-related liver diseases by unknown
RESEARCH Open Access
Analysis of epithelial-mesenchymal
transition markers in the histogenesis of
hepatic progenitor cell in HBV-related liver
diseases
Wei Xu1†, Nong-Rong Wang2,3†, Hua-Feng Wang4†, Qiong Feng5,6†, Jun Deng7†, Zhi-Qiang Gong6, Jian Sun2,
Xiao-Liang Lou2, Xue-Feng Yu2, Lv Zhou8, Jin-Ping Hu8, Xiao-Feng Huang8, Xiao-Qing Qi8, Yan-Juan Deng8,
Rui Gong2, Yan Guo4, Meng-Meng Wang2, Jia-Cheng Xiao4,9 and Huan Deng2,6,8,10*
Abstract
Background: The origin and heterogeneity of hepatic progenitor cells (HPCs) remain unclear. This study aimed to
investigate the involvement of epithelial-mesenchymal transition (EMT) in the histogenesis of HPCs.
Methods: Surgical liver specimens from patients with HBV-related hepatitis and cirrhosis were investigated with
double immunofluorescence labeling to detect antigens associated with HPCs and EMT. Ductular reactions were
subjected to quantitative reverse transcription PCR following isolation by laser capture microdissection. Electron
microscopic examination was performed to find an ultrastructural evidence of EMT.
Results: The number of EpCAM-positive HPCs was proportional to the disease severity. The S100A4 expression of
HPCs was firstly observed in mild hepatitis and increased significantly in moderate hepatitis, but decreased in
severe hepatitis and cirrhosis. The levels of MMP-2, Twist, and Snail increased in direct proportion to the number of
HPCs. Some hepatocytes adjacent to portal tracts in cirrhosis showed positivity for MMP-2. Although CK7 and
E-cadherin levels decreased in mild and moderate hepatitis, HPCs re-expressed both of them in severe hepatitis and
cirrhosis. However, HPCs expressed neither vimentin nor αSMA. The relative mRNA expression levels of EpCAM and
EMT-associated markers supported immunohistochemical results. Electron microscopic examination demonstrated
the existence of intercellular junctions among HPCs, cholangiocytes, and intermediate hepatocyte-like cells.
Conclusion: We provided preliminary evidence for the involvement of EMT in the histogenesis of HPCs from
cholangiocytes in HBV-related liver diseases. HPCs may re-transdifferentiate into hepatocytes, and the differentiation
direction depends, at least in part, on interactions between HPCs and the surrounding microenvironment, especially
the non-resolving inflammation caused by HBV infection.
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Background
It is well known that terminal stage liver diseases can be
treated by liver transplantation with relatively good five-
year survival. However, limited donor organs and rejec-
tion reactions restrict its usage. Thus, it is necessary to
establish a novel strategy. Hepatic progenitor cells
(HPCs)-based therapy is considered to be a promising
replacement for liver transplantation because HPCs are
capable of differentiating into both hepatocyte and
biliary lineage [1, 2]. However, this therapeutic strategy
cannot be fully exploited until the mechanisms under-
lying the histogenesis of HPCs are clearly elucidated. It
is traditionally assumed that HPCs originate in the smal-
lest ramifications of the bile ducts or in locations outside
the liver, such as bone marrow (BM) [3–5]. However,
liver stem cells have never been observed in the adult
liver. Meanwhile, the restricted potential to differentiate
into hepatocytes and cholangiocytes also qualifies HPCs
as true stem cells [6]. Recent studies suggested that
EMT is involved in the pathogenesis of liver cirrhosis, a
common endpoint of most chronic liver diseases. There
is now convincing evidence that TGF-β1 can induce
both cultured hepatocytes and cholangiocytes to
undergo EMT [7–9]. Notably, some cells undergoing
EMT/MET (mesenchymal-epithelial transition) can sim-
ultaneously express epithelial/mesenchymal markers and
HPCs markers [10]. Furthermore, they can repair injured
liver in rodent models [11], raising the exciting possibil-
ity that HPCs may represent a subpopulation of cells
undergoing EMT/MET [12]. However, most available
evidence supporting this hypothesis is indirect and
obtains from rodent models or in vitro studies.
The EMT is a dynamic process that cannot be
followed serially in humans because of technical limi-
tations. In this study, we examined specimens from
patients with benign HBV-related diseases, including
hepatitis and cirrhosis. We used double immunofluores-
cence staining and RT-qPCR (quantitative reverse tran-
scription PCR) to detect characteristic markers that are
associated with HPCs, EMT, and epithelial/mesenchymal
cells. In this study, EpCAM was used for identification
of HPCs, because several studies indicated that EpCAM
is capable of relative higher specificity than other HPCs
markers such as CD133, CK19, and OV-6 [13–15].
S100A4, the human homolog of murine fibroblast-
specific protein 1 (FSP1), has been demonstrated to be a
key marker of early fibroblast lineage development and
EMT [16, 17]. Consequently, loss of cytokeratin (CK)
and adherens junction components such as E-cadherin
promotes the detachment of transitioning cells from
primary sites [18, 19]. At later stages, EMT is accompan-
ied by an increase in motility and matrix invasion, which is
consistent with elevated levels of vimentin and matrix me-
talloproteinases (MMPs) [19]. EMT-derived fibroblast cells
can express α-smooth muscle actin (αSMA) [20]. Mean-
while, several nuclear transcription factors contribute to the
EMTcascade. Twist, a known helix-loop-helix transcription
factor, can directly affect its down-stream element Snail to
suppress the expression of E-cadherin [21–23].
Methods
Patients and clinical data
Sixty patients (42 men and 18 women) with HBV-related
diseases were enrolled. Serum HBV DNA should be
≥2.5 pg/mL and last at least 3 months. Fifteen samples
obtained from liver donors served as control. A part of
each sample was snap-frozen and stored at −80 °C until
being used for laser capture microdissection (LCM).
Clinical data were recorded (Table 1). All patients gave
written informed consent to participate in the study in ac-
cordance with the Helsinki Declaration, and this study
was approved by the Regional Ethics Committee (Medical
Ethics Committee of The Fourth Affiliated Hospital of
Nanchang University and Ruijin Hospital, School of
Medicine, Shanghai Jiaotong University).
Histopathological examination
The histopathological evaluation of all sections was per-
formed by two independent researchers (JH Mei and YQ
Xiao) who were blinded regarding patient details. The
method proposed by Bedossa et al. was served as grading
standard [24] (Table 2).
Double immunofluorescence labeling and morphometric
determinations
The formalin fixed and paraffin embedded tissues were
cut at 2- to 5-μm and retrieved in citrate buffer (pH 6.0)
at 95 °C −99 °C for 15 min. These slides were then
blocked with 20% BSA before the incubation with a
cocktail for EpCAM and one of the EMT-associated
markers at 4 °C overnight (Table 3). Two different anti-
bodies for EpCAM were employed in this study to avoid
cross-reactions (Table 3). Serial sections from three
breast ductal carcinoma samples served as the positive
control to compare the sensitivity and specificity of the
two different EpCAM antibodies according to manufac-
tory’s instruments. Two independent pathologists, who
were blinded regarding staining details, evaluated and
recorded the extent and intensity of sections respectively
by using the following arbitrary scale: 0: ≤ 25%, no stain-
ing; 1: 26–50%, weak staining; 2: 51–75%, moderate
staining; 3: 76–100%, strong staining. Statistical analysis
based on the accumulated scores suggested that there
were no significant differences between the two anti-
bodies (p < 0.01). FITC or TRITC-conjugated secondary
antibodies (Jackson Immunoresearch, USA) were incu-
bated with the pretreated slides at room temperature for
60 min. The dilutions were 1:100 and 1:150, respectively.
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Table 1 Clinical, biochemical and histopathological characteristics of patients with HBV associated diseases
Case Sex Age (years) Disease AST (IU/L) ALT (IU/L) Albumin (g/L) Total bilirubin (μmol/L) Platelet (×109/L) Serum AFP (n/g/mL)
1 M 28 Hepatitis (Mild) 25 20 35 15.7 62 5.8
2 M 49 Hepatitis (Mild) 17 22 38 19.3 321 5.2
3 F 27 Hepatitis (Mild) 18 31 30 31.9 158 10
4 F 58 Hepatitis (Mild) 21 11 41 19.2 71 3.39
5 M 56 Hepatitis (Mild) 21 28 41 12.4 240 9.01
6 M 50 Hepatitis (Mild) 33 25 59 28.5 257 5.2
7 M 39 Hepatitis (Mild) 18 15 24 12 158 3.2
8 M 24 Hepatitis (Mild) 21 19 36 10.5 182 6.82
9 M 28 Hepatitis (Mild) 39 50 41 22.9 234 4.45
10 M 32 Hepatitis (Mild) 25 26 39 12.3 120 5.3
11 M 36 Hepatitis (Mild) 14 16 41 19.3 178 4.3
12 M 28 Hepatitis (Mild) 24 18 28 5.6 205 5.25
13 M 22 Hepatitis (Mild) 30 24 39 23.1 124 2.8
14 M 42 Hepatitis (Mild) 27 31 29 22.2 94 9.4
15 F 47 Hepatitis (Mild) 22 23 44 16 322 2.6
16 F 31 Hepatitis (Moderate) 43 41 28 21.3 167 10.2
17 F 38 Hepatitis (Moderate) 30 29 41 22.4 203 4.2
18 M 39 Hepatitis (Moderate) 18 17 30 21.4 205 6.2
19 M 41 Hepatitis (Moderate) 25 23 35 29 231 2.9
20 M 32 Hepatitis (Moderate) 31 29 27 17.4 160 1.84
21 M 28 Hepatitis (Moderate) 40 47 42 13.4 205 9.2
22 M 57 Hepatitis (Moderate) 22 19 42 21.8 265 4.28
23 F 41 Hepatitis (Moderate) 25 30 37 10.8 46 4.38
24 F 57 Hepatitis (Moderate) 21 12 19 31.3 254 3.21
25 M 39 Hepatitis (Moderate) 28 36 32 14.8 269 3.42
26 M 24 Hepatitis (Moderate) 39 21 57 19.9 189 3.02
27 M 60 Hepatitis (Moderate) 21 14 30 12.4 94 3.59
28 F 25 Hepatitis (Moderate) 32 21 51 20 109 2.5
29 F 39 Hepatitis (Moderate) 23 26 41 21.3 206 11.7
30 M 42 Hepatitis (Moderate) 48 35 44 25.1 207 8.2
31 F 39 Hepatitis (Severe) 54 92 26 35 307 10.6
32 M 52 Hepatitis (Severe) 35 37 18 15 184 1.23
33 M 36 Hepatitis (Severe) 23 71 39 23.1 159 9.08
34 M 21 Hepatitis (Severe) 35 49 25 38.1 93 3.57
35 M 31 Hepatitis (Severe) 28 58 62 29.5 222 4.9
36 M 39 Hepatitis (Severe) 23 31 31 16.6 81 2.2
37 M 26 Hepatitis (Severe) 18 24 50 20.7 152 8.1
38 F 27 Hepatitis (Severe) 29 42 41 29.1 121 2.7
39 M 40 Hepatitis (Severe) 7 15 25 15.2 106 3.9
40 M 47 Hepatitis (Severe) 37 27 31 8.2 83 4.6
41 M 33 Hepatitis (Severe) 24 62 28 43.2 119 3.12
42 M 51 Hepatitis (Severe) 16 36 32 24.3 132 7.9
43 M 32 Hepatitis (Severe) 41 61 18 16.8 182 10
44 F 41 Hepatitis (Severe) 66 34 30 38.7 204 4.33
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Finally, the slides were washed with PBS for three times
and mounted with anti-fade medium (Vector, USA). A
Nikon 80i microscope with the Intensilight fluorescence
set and DS-Ri2 camera (Nikon, Japan) was used to
perform the image analysis.
HPCs were considered to be small to medium
EpCAM-positive cells localizing within ductular reac-
tions (DRs). Counting of positive cells was conducted on
sections with an immunofluorescence microscope. The
corresponding number of non-overlapping fields in the
section was counted using the 40× objective. The
average number of positive cells in each square centi-
meter was calculated for each specimen.
LCM and RT-qPCR
Frozen sections were placed onto PET-membrane slides
(Leica Microdissect, Herborn, Germany) and briefly
stained with hematoxylin and eosin (H&E). DRs were
dissected using LCM with a Leica SVS LMD System
(Leica Microsystems, Wetzlar, Germany). A sufficient
number of cells were obtained from 5 to 10 tissue sec-
tions. RNA was isolated using an RNeasy Micro Kit
(Qiagen, Hilden, Germany) and then evaluated by the
Agilent 2100 bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA) as in a previous study [13]. RT-qPCR
was performed with a Select cDNA Synthesis Kit
(Bio-Rad, California, USA). Relative mRNA levels of
targeted genes were measured by RT-qPCR during
40 cycles and expressed as ΔCt values when compared to
GAPDH (primer sequences see Table 4) [25].
Transmission electron microscopic (EM) examination
All tissues were fixed in 4% glutaraldehyde in 0.1 m
phosphate buffer pH 7.3 and embedded in Epon 812.
Following double staining with uranyl acetate and lead
Table 1 Clinical, biochemical and histopathological characteristics of patients with HBV associated diseases (Continued)
45 M 25 Hepatitis (Severe) 20 15 50 23.4 310 3.8
46 F 51 non-HCC cirrhosis 12 41 48 36.2 49 9.2
47 M 47 non-HCC cirrhosis 31 21 42 36.9 69 4.9
48 M 38 non-HCC cirrhosis 27 33 26 13.9 891 4.27
49 M 40 non-HCC cirrhosis 47 36 40 26.1 104 21.34
50 F 41 non-HCC cirrhosis 30 14 28 40.3 71 3.6
51 M 55 non-HCC cirrhosis 38 10 28 28.4 158 6.87
52 F 60 non-HCC cirrhosis 20 51 32 11.4 175 5.74
53 M 49 non-HCC cirrhosis 44 27 35 19.3 92 3.56
54 M 54 non-HCC cirrhosis 20 42 21 14.3 60 7.24
55 M 59 non-HCC cirrhosis 25 26 46 18.5 127 2.3
56 M 48 non-HCC cirrhosis 19 15 39 21.2 115 6.8
57 F 32 non-HCC cirrhosis 307 342 49 29.3 110 7.6
58 M 56 non-HCC cirrhosis 22 19 26 20.6 172 8.3
59 F 53 non-HCC cirrhosis 31 26 24 18.2 77 2.48
60 F 47 non-HCC cirrhosis 20 25 51 21.9 51 3.9
Table 2 Histological activity of liver biopsy of chronic hepatitis B
Histological Activity Histological Feature
Mild (A1) PMN = 0 LN = 1
PMN = 1 LN = 0, 1
Moderate (A2) PMN = 0 LN = 2
PMN = 1 LN = 2
PMN = 2 LN = 0, 1
Severe (A3) PMN = 2 LN = 2
PMN = 3 LN = 0, 1, 2
PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate, 3, severe; LN, lobular
necrosis; 0, no or mild; 1, moderate; 2, severe
Table 3 Summary of primary antibody used for
immunohistochemistry
Antibody Isotype Supplier Dilution
EpCAM IgG1(rabbit) Epitomics 1:300
EpCAM IgG1(mouse) abcam 1:100
Cytokeratin 7 IgG1(mouse) DAKO 1:100
E-Cadherin IgG1(mouse) DAKO 1:50
S100A4 IgG(rabbit) abcam 1:50
MMP-2 IgG(rabbit) abcam 1:250
Twist IgG1(mouse) abcam 1:150
Snail IgG(rabbit) abcam 1:100
Vimentin IgG1(mouse) DAKO 1:100
α-SMA IgG2a(mouse) DAKO 1:100
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citrate, the sections were examined using a Philips
CM120 transmission EM.
Statistical analysis
Continuous normally distributed variables are repre-
sented as mean ± SD. The inflammatory grade was sum-
marized by the median. ANOVA was used to evaluate
the difference among the comparative mRNA expression
of each gene in normal, hepatitis and cirrhosis speci-
mens. The LSD-t test was applied for post-hoc compari-
sons. P < 0.05 was considered statistically significant.
Data analyses were carried out using SPSS version 13.0
for Windows (SPSS, Inc., Chicago, USA).
Results
Expression of EMT markers in HBV-related liver diseases
In normal liver, DRs were absent and cholangiocytes in
intrahepatic bile duct showed positivity for CK7 and E-
cadherin (Figs. 1a, and 2a, f). They did not express EpCAM
or EMT-associated markers (Figs. 1f, k and 2k, 2p).
Although a definite phenotypic marker has not yet
been developed, S100A4 has been described as one of
the earliest makers and activators of EMT [17]. In
sections from patients with mild and moderate in-
flammation, some but not all S100A4-positive cells
expressed the HPC marker EpCAM (n = 1.19 ± 0.68 per
cm2 and n = 3.09 ± 0.52 per cm2, respectively) (Fig. 1g, h).
Noteworthy, only a few of HPCs in sections of severe
Table 4 The sequences of primers used in qRT-PCR
Gene Sense Antisense Product (bp)
EpCAM CTGGACTGGAATGCTGAG CGAAGATGACGATGAGGAT 178
S100A4 GATGAGCAACTTGGACAGCAA CTGGGCTGCTTATCTGGGAAG 123
MMP-2 CCGTCGCCCATCATCAAGTT CTGTCTGGGGCAGTCCAAAG 169
Twist GAATGACCGCTTCGCCAACTA CCGCATCTCCTCCTCGTAGA 136
Snail ACTACTGCTGAGCGTGAGATTG CGATGAAGGATGGCTGGAACA 199
CK7 TTGTGGTGCTGAAGAAGG CTGTCAACTCCGTCTCATT 123
E-cadherin CGAGAGCTACACGTTCACGG GTGTCGAGGGAAAAATAGGCTG 117
Vimentin GACGCCATCAACACCGAGTT CTTTGTCGTTGGTTAGCTGGT 238
αSMA GTGTTGCCCCTGAAGAGCAT GCTGGGACATTGAAAGTCTCA 109
GAPDH GAAGATGGTGATGGGATTTC GAAGGTGAAGGTCGGAGT 230
Fig. 1 The expressions of S100A4 and MMP-2 in HPCs. a, f, k In sections from normal liver, parenchymal cells expressed neither S100A4 nor MMP-2
(original magnification × 200). b, g, l Some HPCs in mild hepatitis showed immunopositivity for EpCAM, rather than MMP-2. (original magnification ×
200, inserts, original magnification × 400). c, h, m Majority of HPCs in moderate hepatitis expressed strong-diffuse cytoplasmic positivity for S100A4 and
MMP-2 (original magnification × 200, inserts, original magnification × 400). d, i, n The expression level of S100A4 decreased significantly in HPCs from
severe hepatitis. But HPCs expressed a high level of MMP-2 (original magnification × 200, inserts, original magnification × 400). e, j, o HPCs in
cirrhosis sections showed negativity for S100A4. Both HPCs and intermediate hepatocytes (arrow) adjacent to portal tracts expressed MMP-2
(original magnification × 200)
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inflammation and cirrhosis expressed S100A4 (n = 1.02 ±
0.44 per cm2 and n = 0.26 ± 0.17 per cm2) (Fig. 1i, j).
MMPs comprise a large family that regulates essential
steps of embryogenesis and wound healing. Our results
showed that HPCs and hepatocytes in sections of mild
hepatitis were negative for MMP-2 (Fig. 1l). In moderate
and severe hepatitis, a portion of HPCs expressed
MMP-2 (n = 2.45 ± 0.98 per cm2 and n = 2.45 ± 0.98 per
cm2, respectively) (Fig. 1m, n). Some intermediate
hepatocyte-like cells (IHLCs) adjacent to portal tracts
from patients with cirrhosis showed immunopositivity
for MMP-2 rather than EpCAM (Fig. 1o).
The proteomic features of EMT also include the loss
of epithelial markers. Although almost all of HPCs
within DRs of mild hepatitis co-expressed CK7 and
E-cadherin (n = 1.77 ± 0.83 per cm2 and n = 1.42 ± 0.76
per cm2, respectively), a few of HPCs displayed neither
of them (Fig. 2b, g). The number of CK7- or E-cadherin-
positive HPCs decreased significantly in moderate hepa-
titis as compared to mild hepatitis (n = 0.65 ± 0.33 per
cm2 and n = 0.78 ± 0.45 per cm2, P < 0.05) (Fig. 2c, h).
Noteworthy, HPCs expressed elevated levels of CK7 and E-
cadherin in severe hepatitis and cirrhosis as compared to
mild hepatitis (n = 2.11 ± 0.64 per cm2, 3.08 ± 0.52 per cm2,
and n = 1.87 ± 0.56 per cm2, 3.18 ± 0.49 per cm2, P < 0.05)
(Fig. 2d, e, i, and j).
Repression of E-cadherin by transcriptional regula-
tors such as Twist and Snail serves as a key event
during EMT [26]. Nuclear positivity for Twist or Snail
in HPCs was firstly detected in sections of mild hepatitis
(n = 1.62 ± 0.49 per cm2 and n = 1.70 ± 0.52 per cm2,
respectively) (Fig. 2l, q), and the number of Twist- or
Snail-positive HPCs was proportional to the severity of
HBV-related disease (n = 2.65 ± 0.83, 3.79 ± 0.33, 4.91 ±
0.39 per cm2 and n = 2.41 ± 0.45, 3.66 ± 0.81, 4.78 ± 0.53
per cm2, respectively, P < 0.05).
The expression of αSMA and vimentin during EMT
indicates the transdifferentiation from epithelial cells
into mature mesenchymal cells such as myofibroblasts.
In sections of normal, hepatitis, and cirrhotic liver,
HPCs, and parenchymal cells did not express αSMA or
vimentin (data not show).
Comparison of mRNA expression of EMT-associated
markers
We employed LCM to collect DRs (Fig. 3). Total RNA ex-
tracted from the microdissected samples was 37–102 ng.
Consistent with the double immunofluorescence staining
Fig. 2 The expressions of CK7 and E-cadherin in HPCs. a, f Cholangiocytes in normal liver exhibited positivity for CK7 and E-cadherin rather than EpCAM
(original magnification × 200). b, g HPCs within DRs of mild hepatitis co-expressed CK7 and EpCAM. The down-regulated expression of E-cadherin was
detected in DRs of cirrhosis (original magnification × 200). c, h The number of CK7- or E-cadherin-positivity HPCs decreased significantly in moderate
hepatitis (original magnification × 200). d, i In sections of severe hepatitis, the number of CK7- or E-cadherin-positivity HPCs increased (original
magnification × 200). e, j Majority of HPCs within DRs of cirrhosis re-expressed CK7 or E-cadherin (original magnification × 200). k, p Cholangiocytes and
hepatocytes in the normal liver did not express Twist and Snail (original magnification × 200). l-o Twist-positive HPCs numbers increased in direct
proportion to disease severity (original magnification × 200). q-t Hepatitis and cirrhosis resulted in the elevated level of Snail (original magnification × 200)
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results, RT-qPCR showed that normal bile ducts did not
show aberrant expression of EpCAM nor EMT-associated
markers. The elevated mRNA levels of EpCAM, S100A4,
Twist, or Snail were firstly confirmed in mild hepatitis
and showed a positive relationship with inflammation
severity. S100A4 mRNA expression in severe inflamma-
tion liver specimens was significantly higher than that in
cirrhotic liver (P < 0.001) (Fig. 4). The expression of
MMP-2 increased significantly in moderate, severe hepa-
titis and cirrhotic liver (P < 0.001). DRs in HBV-related
diseases did not express vimentin and αSMA. The reduc-
tion in mRNA expression of the epithelial markers CK7
and E-cadherin was detected in mild and moderate
hepatitis (P < 0.001). However, their expression levels
increased and paralleled the severity of diseases in severe
hepatitis and cirrhosis (P < 0.001) (Fig. 4).
Ultrastructural findings
HPCs, characterized by their oval shape, small size (7 to
15 μm in diameter) and scanty electron-dense cytoplasm,
Fig. 3 Hematoxylin and eosin staining of liver tissue sections before (left) and after (right) laser capture microdissection. a Bile ducts or DRs were
isolated from tissue sections of normal liver, b mild hepatitis, c moderate hepatitis, d severe hepatitis, and e cirrhosis
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existed in all specimens of HBV-related diseases (Fig. 5a).
Intercellular junctions were noted between HPCs and
some IHLCs. The latter is characterized by abundant cyto-
plasm and mitochondria, fewer tonofilament bundles
compared with HPCs (Fig. 5a, b). The cellular junctions
were also observed between HPCs, cholangiocytes, and
intermediate hepatocyte-like cells, suggesting a transdiffer-
entiation from mature cholangiocyte to immature hepato-
cyte (Fig. 5a). Additionally, HPCs at the portal tract/
hepatocyte interface contained a greater number of tonofi-
lament bundles than HPCs in the periportal tract,
suggesting the intriguing possibility of epithelial pheno-
type reacquisition (Fig. 5b).
Discussion
Despite recent advances in pathophysiology, the histo-
genesis and heterogeneity of HPCs in humans are
matters of debate. In this study, we combined data from
immunophenotypic and mRNA studies with ultrastruc-
tural examination to provide preliminary evidence for
the involvement of EMT in the histogenesis of HPCs in
HBV-related liver diseases.
Fig. 4 mRNA expression levels of HPCs after tissue picking by laser capture microdissection. The expression levels of EpCAM, S100A4, MMP-2, CK7,
E-cadherin, Twist, and Snail were detected by RT-qPCR. * mild hepatitis versus normal control, P <0.05;╪ moderate hepatitis versus mild hepatitis,
p <0.05; § severe hepatitis versus moderate hepatitis, P < 0.05;▲ cirrhosis versus severe hepatitis, P < 0.05; ** cirrhosis versus severe hepatitis, P > 0.05
Fig. 5 EM examination was performed to find ultrastructural evidence for the transition. a Three HPCs identified by EM. An IHLC with more cytoplasm
and mitochondria than HPCs was in close association with HPCs. b There were intercellular junctions among HPCs, cholangiocytes, and intermediate
hepatocyte (arrow). Tonofilament bundles in cytoplasm of HPCs indicated the reacquisition of epithelial characteristic (arrowhead)
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S100A4, which modifies cell motility and growth
through interactions with the cytoskeleton and the
C-terminus of p53, has been proposed as an early
marker of EMT [17]. Co-expression of EpCAM and
S100A4 provided clear evidence that although these
HPCs have an epithelial phenotype, they are actively
engaged in EMT. HPCs also expressed another import-
ant EMT marker MMP-2, which possesses the ability to
degrade basement membrane and increases cell motility
[27]. The activity of MMPs can alter the expression of
E-cadherin and vimentin and promote the EMT process
[28]. High levels of MMP-2 may promote the dispatch
of HPCs from DRs.
A hallmark of EMT is the aberrant expression of
E-cadherin (encoded by CDH1), which is always linked
to the tumorigenesis of many epithelial cancers [29].
E-cadherin is a key factor of cell-cell adhesion junctions
in the maintenance of cell polarity and structure. Recent
studies uncovered its critical roles in proliferation, differ-
entiation, and carcinogenesis. Analogous to cholangitis,
the loss of E-cadherin in the liver contributes to the
periportal inflammation and later periductal fibrosis
[30]. A study making use of a transgenic mouse model
where the expression of cre was directed by the albumin
enhancer/promoter (termed Alb-cre) demonstrated that
these lesions arose as a consequence of the loss of
E-cadherin in the cholangiocytes [30]. The reexpression
of cre in hepatocytes could not attenuate the effects [31,
32]. In this study, the expression of E-cadherin and CK7
in HPCs decreased significantly from mild hepatitis to
moderate hepatitis, revealing that these transitioning
cells might derive from epithelial cells within DRs and
were losing cell-cell contacts. However, the number and
ratio of E-cadherin- or CK7-positive HPCs increased in
sections of severe hepatitis and cirrhosis, suggesting that
the transitioning cells might reverse the cascade and
reacquire epithelial characteristics.
Twist is a core element during EMT process [22]. The
overexpression or promoter methylation of Twist is
always associated, in a statistically significant manner,
with the tumor aggressiveness [33–35]. Activated Twist
binds to the promoter region of E-cadherin and
transcriptionally downregulates E-cadherin expression
[36]. Together with the polycomb protein Bmi1, Twist
contributes to the stemness of cells, which is one of the
most important features of HPCs [22].
Snail is a zinc-finger transcription factor, which can
induce EMT by repression of E-cadherin [23]. TGF-β
promotes EMT by up-regulating Snail expression via a
Smad-dependent pathway. Snail forms a transcriptional
repressor complex with SMAD3/4. The complex then
targets the adjacent E-boxes and Smad-binding elements
in genes encoding junction proteins such as E-cadherin,
CAR and occluding [37].
In all hepatitis and cirrhotic sections, the majority of
HPCs within DRs or bile ducts expressed high levels of
Twist or Snail, which are proportional to the severity of
HBV-related diseases. RT-qPCR further validated these
findings, indicating that Twist and Snail were involved
in the EMT process of HPCs via the repression of E-cad-
herin in HBV-related diseases.
We tried to obtain further evidence for the transdiffer-
entiation from HPCs into mature mesenchymal cells by
using antibodies for αSMA and vimentin. However,
neither cholangiocytes nor hepatocytes expressed αSMA
or vimentin in this study. We considered two possibil-
ities for this situation. First, αSMA- or vimentin-positive
HPCs may detach from DRs because of an increase in
motility and matrix invasion [38]. Hence, these tran-
sitioning cells at an advanced stage of EMT do not
express EpCAM and detach from DRs. Second, as
reversibility is an important feature of EMT, it is tempt-
ing to speculate that these transitioning cells may re-
transdifferentiate into parenchymal cells through MET
under certain conditions.
Although we did not obtain substantial results about
whether hepatocytes could transdifferentiate into HPCs
through EMT, some periportal intermediate hepatocytes
in sections from cirrhotic livers showed immunopositiv-
ity for MMP-2. We postulated an intriguing possibility
that, at least in HBV-related liver diseases, intermediate
hepatocytes may represent daughter cells of HPCs rather
than a cellular origin of HPCs. Ultrastructural evidence
that intercellular junctions existed between HPCs and
intermediate hepatocytes further supported this hypoth-
esis. Consistent with our findings, a recent study based
on an established rodent model provided convincing
evidence for challenging the concept that hepatocytes
can acquire a mesenchymal phenotype in vivo via EMT
[39]. In contrast, previous studies demonstrated that
hepatocytes may also be capable of undergoing EMT in
vitro [40, 41]. Furthermore, an elaborate study indicated
that the Hippo signal pathway can direct hepatocytes to
transdifferentiate into HPC-like cells and finally mimic
an atypical ductular reaction [42]. We believe that
different microenvironments may result in different
outcomes. Most recently, an elaborate study provided
supporting evidence [43]. Foetal HPCs can form hepatic
cysts characterized by Albumin-positive/CK19-negative
in vitro. However, if foetal HPCs are pre-cultured on
gelatin-coated dishes, they are capable of forming
cholangiocytic cysts expressing Albumin-negative/CK19-
positive, similar to that of HPCs [43]. This cholangiocytic
cysts formation can be hampered by hepatic maturation
factors, such as hepatocyte growth factor (HGF) and
oncostatin M (OSM). Of note, the study also indicated
that TGF-β antagonist A-8301 plays an important role in
the cholangiocytic cysts formation. It seems that this
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conclusion is consistent with our hypothesis and observa-
tions in vivo. TGF-β derived from portal parenchymal
cells or infiltrating immune cells promotes the entrance of
cholangiocytes into the EMT cascade and transdiffe-
rentiation into hepatocyte-like cells. However, further
experiments will be required to gain more insights into
the regulatory mechanisms.
Chronic HBV infection may serve as a powerful driver
of EMT. The regeneration capacity of mature hepato-
cytes is overwhelmed during massive or chronic liver
infection. Various cytokines released from injured paren-
chymal cells establish a stable inflammatory infiltrate
through the recruitment of leukocytes from blood [44].
T-cells mediate both liver injury and viral clearance in ani-
mal models of HBV infection and produce regulatory cy-
tokines such as TGF-β, a powerful driver of EMT [45–47].
Furthermore, T-cells can express integrin, allowing the
adhesion to E-cadherin of the epithelium [48]. We specu-
late that high level of TGF-β induces EMT of DRs at the
portal tract. These transitioning cells are capable of
transdifferentiation into HPCs and movement towards
injured sites, resembling chemotaxis. Since the number of
immune cells and parenchymal cells decreases and results
in the reduced TGF-β1 level at the lobule boundaries, the
transitioning cells/HPCs may reverse EMT cascade and
re-transdifferentiate into hepatic lineage to restore paren-
chyma [12]. The ultrastructural result that tonofilament
bundles reoccurred in the cytoplasm of HPCs favors this
opinion.
Non-resolving inflammation is established when the
recruitment of inflammatory cells outstrips the mecha-
nisms of resolution, including the apoptosis and the
migration through lymphatics [49]. Non-resolving in-
flammation is responsible for abnormally elevated
expression of TGF-β1 and the receptor for advanced
glycation endproducts (RAGE), which plays an import-
ant role in the regulation of HPCs activation [50].
Consequently, most of the HPCs undergo complete
EMT and differentiate into mature mesenchymal cells.
The repair process is mainly fibrogenic because of the
excess production and deposition of extracellular matrix
components. The genetic or epigenetic changes may
increase the susceptibility of HPCs to the detrimental
microenvironment and result in self-renewing cells.
Finally, HPCs or their progeny may transform to malig-
nant cells because of the further accumulation of other
alterations [50].
Conclusion
Taken together, our study provided preliminary evidence
that, at least in HBV-related hepatitis and cirrhosis, EMT
is associated with the histogenesis and differentiation of
HPCs. Ultrastructural results confirmed the direct inter-
action between HPCs and intermediate hepatocyte-like
cells. The presence of tonofilament bundles in HPCs
combined with double immunofluorescence staining
results that they re-expressed epithelial markers CK7 and
E-cadherin, rather than mesenchymal markers αSMA and
vimentin, suggested that these transitioning HPCs may
not complete the EMT cascade and launch the reverse
process MET to gain epithelial features. However, this
study mainly focused on human pathological tissues.
Further experiments, especially in vitro and animal model
studies, are required to explore the exact role of regulatory
cytokines and microenvironment.
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